Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9228 USD | +1.13% | -9.53% | -33.13% |
04-26 | Bluebird bio Gets Nasdaq Notice for Late Filing of Annual Report | MT |
03-27 | Wells Fargo Trims Price Target on Bluebird Bio to $3 From $4, Maintains Equalweight Rating | MT |
Business Summary
Number of employees: 323
Sales per Business
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Gene Therapies
76.1
%
| 3 | 77.8 % | 3 | 76.1 % | -3.89% |
Other
23.9
%
| 1 | 22.2 % | 1 | 23.9 % | +5.67% |
Sales per region
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 4 | 100.0 % | 4 | 100.0 % | -1.77% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Andrew Obenshain
CEO | Chief Executive Officer | 51 | 31/12/15 |
Director of Finance/CFO | 51 | 06/11/22 | |
Melissa Bonner
CTO | Chief Tech/Sci/R&D Officer | - | 30/11/21 |
Richard Colvin
CTO | Chief Tech/Sci/R&D Officer | 58 | 31/12/17 |
Thomas Klima
COO | Chief Operating Officer | 52 | 09/05/21 |
Nick Leschly
BRD | Director/Board Member | 51 | 28/02/10 |
Courtney OLeary
IRC | Investor Relations Contact | - | - |
Andrea Walton
HRO | Human Resources Officer | - | 31/12/21 |
Corporate Officer/Principal | 51 | 31/08/11 | |
Joseph Vittiglio
LAW | General Counsel | 52 | 02/01/23 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Vachon
CHM | Chairman | 65 | 15/07/14 |
Nick Leschly
BRD | Director/Board Member | 51 | 28/02/10 |
Richard Paulson
BRD | Director/Board Member | 56 | 02/04/23 |
John Agwunobi
BRD | Director/Board Member | 59 | 07/06/17 |
Director/Board Member | 47 | 14/10/21 | |
Andrew Obenshain
CEO | Chief Executive Officer | 51 | 31/12/15 |
Najoh Tita
BRD | Director/Board Member | - | 28/09/21 |
Director/Board Member | - | 06/03/22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 190,355,471 | 189,636,689 ( 99.62 %) | 0 | 99.62 % |
Company contact information
Sector
Sales per Business
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.13% | 178M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- BLUE Stock
- Company bluebird bio, Inc.